Merck Comes Prepared This Time As Sugammadex Faces Second Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
After failing to submit safety data on time during the drug’s first FDA review, Merck has its data together and is armed with a new hypersensitivity study in advance of the second panel review for its anesthesia product.